{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:27:08Z","timestamp":1753892828503,"version":"3.41.2"},"reference-count":18,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T00:00:00Z","timestamp":1748908800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003509","name":"\u00d6rebro Universitet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003509","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:sec><jats:title>Introduction and objective<\/jats:title><jats:p>The cholinergic system has broad implications for affective and cognitive processes, which makes it pertinent for the psychopathology and treatment of mental disorders. Questions concerning its role in schizophrenia, a chronic disorder characterized by psychosis, emotional blunting and cognitive deficits, have been made particularly relevant due to the recent Food and Drug Administration (FDA) approval of a muscarinic agonist as an antipsychotic agent. The present paper details the protocol for a scoping review that will map models, evidence and research gaps concerning the role of the cholinergic system in the positive, negative and cognitive domains implicated in the psychopathology of schizophrenia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods and analysis<\/jats:title><jats:p>The scoping review will be conducted according to JBI (formerly the Joanna Briggs institute) methodology, using articles from the following databases: PubMed, Embase, Scopus, Cochrane Central Register of Controlled Trials and PsycInfo. Two independent reviewers will screen the articles using title and abstract, after which full text-analysis will determine inclusion. Only published original peer-reviewed English-language studies from the last 20 years that pertain to the review objective will be included. Clinical studies will be assessed for methodological quality and risk of bias. The results, which the reviewers will extract independently of each other using a data extraction tool, will be presented in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analysis Protocol Extension for Scoping Reviews (PRISMA-ScR).<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>Clarifying the research gaps in the field can indicate where future pre-clinical and clinical studies and systematic reviews can be worthwhile, and the risk of bias assessment aids in this by stratifying the included clinical trials according to quality. However, the language and publication date restrictions risk excluding relevant studies, which can introduce bias.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpsyt.2025.1593211","type":"journal-article","created":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T15:00:09Z","timestamp":1748962809000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Role of the cholinergic system in the psychopathology and treatment of schizophrenia: a protocol for a scoping review"],"prefix":"10.3389","volume":"16","author":[{"given":"Michal","family":"Haczkiewicz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrika","family":"Hyl\u00e9n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mussie","family":"Msghina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.schres.2013.05.028","article-title":"Definition and description of schizophrenia in the DSM-5","volume":"150","author":"Tandon","year":"2013","journal-title":"Schizophr Res"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/mp.2012.47","article-title":"Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents","volume":"17","author":"Miyamoto","year":"2012","journal-title":"Mol Psychiatry"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sby058","article-title":"Global epidemiology and burden of schizophrenia: findings from the global burden of disease study 2016","volume":"44","author":"Charlson","year":"2018","journal-title":"Schizophr Bull"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.24869\/psyd.2017.108","article-title":"Causes of mortality in schizophrenia: an updated review of european studies","volume":"29","author":"Piotrowski","year":"2017","journal-title":"Psychiatr Danub"},{"key":"B5","unstructured":"ghe2019_daly-methods.pdf"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2012.08.036","article-title":"Acetylcholine as a neuromodulator: cholinergic signaling shapes nervous system function and behavior","volume":"76","author":"Picciotto","year":"2012","journal-title":"Neuron"},{"key":"B7","doi-asserted-by":"publisher","first-page":"103608","DOI":"10.1016\/j.concog.2023.103608","article-title":"Acetylcholine and metacognition during sleep","volume":"117","author":"Gott","year":"2024","journal-title":"Conscious Cogn"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/0301-0082(86)90016-X","article-title":"The cholinergic systems in brain and spinal cord","volume":"26","author":"K\u00e1sa","year":"1986","journal-title":"Prog Neurobiol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fnsyn.2014.00022","article-title":"Striatal cholinergic interneuron regulation and circuit effects","volume":"6","author":"Lim","year":"2014","journal-title":"Front Synaptic Neurosci"},{"key":"B10","unstructured":"FDA approves drug with new mechanism of action for treatment of schizophrenia\n          \n          \n          \n          2024"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852916000407","article-title":"Mechanism of action of pimavanserin in Parkinson\u2019s disease psychosis: targeting serotonin 5HT2A and 5HT2C receptors","volume":"21","author":"Stahl","year":"2016","journal-title":"CNS Spectr"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.51.7.928","article-title":"Misuse of anticholinergic drugs by people with serious mental illness.","volume":"51","author":"Buhrich","year":"2000","journal-title":"Psychiatr Serv"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-004-1940-5","article-title":"The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine","volume":"177","author":"Weiner","year":"2004","journal-title":"Psychopharmacol (Berl)"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1301279","article-title":"Evaluation of N-desmethylclozapine as a potential antipsychotic--Preclinical studies","volume":"32","author":"Natesan","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"B15","doi-asserted-by":"publisher","first-page":"953","DOI":"10.11124\/JBIES-21-00242","article-title":"Best practice guidance and reporting items for the development of scoping review protocols","volume":"20","author":"Peters","year":"2022","journal-title":"JBI Evid Synth"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.46658\/JBIMES-24-01","article-title":"JBI manual for evidence synthesis","author":"Aromataris","year":"2024","journal-title":"JBI"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.7326\/M18-0850","article-title":"PRISMA extension for scoping reviews (PRISMA-scR): checklist and explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann Intern Med"},{"key":"B18","unstructured":"Granskningsmallar"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2025.1593211\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T15:00:11Z","timestamp":1748962811000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2025.1593211\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,3]]},"references-count":18,"alternative-id":["10.3389\/fpsyt.2025.1593211"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2025.1593211","relation":{},"ISSN":["1664-0640"],"issn-type":[{"type":"electronic","value":"1664-0640"}],"subject":[],"published":{"date-parts":[[2025,6,3]]},"article-number":"1593211"}}